Fact based stock research
Hologic (NasdaqGS:HOLX)


Hologic stock research in summary

hologic.com


Hologic shares have a SELL rating. While they are good value, they show below average growth, and are riskily financed. We recommend selling Hologic shares.


Latest Obermatt Ranks


Country USA
Industry Health Care Equipment
Index NASDAQ 100, NASDAQ, S&P 500, D.J. US Medical Equipment
Size class X-Large

March 22, 2018. Top 10 stocks updated on Top 10 schedule or at least quarterly. ()


Achievements

Top 10 Stock






 

Research History: Hologic

STOCK RESEARCH SUMMARY 2015 2016 2017 2018
STOCK VALUE RANKS
36
31
54
61
STOCK GROWTH RANKS
70
33
17
15
STOCK SAFETY RANKS
6
4
12
11
COMBINED STOCK RANKS
16
1
13
9

Last update of Combined Rank: 22-Mar-2018. Stock research history is based on the Obermatt Method. The higher the rank, the better is Hologic in the corresponding investment strategy.


Value Metrics in Detail

Last update of Value Rank: 22-Mar-2018. Stock analysis on value ratios: The higher the rank, the lower the value ratio of Hologic; except for dividend yield where the rank is higher, the higher the yield.


Growth Metrics in Detail

GROWTH METRICS 2015 2016 2017 2018
REVENUE GROWTH
39
19
42
37
PROFIT GROWTH
76
52
24
8
STOCK RETURNS
77
42
20
35
CONSOLIDATED RANK: GROWTH
70
33
17
15

Financial reporting date of Growth Rank: 30-Dec-2017. Stock analysis on growth metrics: The higher the rank, the higher the growth and returns of Hologic.


Safety Metrics in Detail

SAFETY METRICS 2015 2016 2017 2018
LEVERAGE
2
4
16
16
REFINANCING
19
22
LIQUIDITY
38
39
48
54
CONSOLIDATED RANK: SAFETY
6
4
12
11

Financial reporting date of Safety Rank: 30-Dec-2017. Stock analysis on safety metrics: The higher the rank, the lower the leverage of Hologic and the more cash is available to service its debt.


Stock analysis by the purely financial fact-based Obermatt Method for the investment strategies Value, Growth and Safety for Hologic from March 22, 2018.